European Journal of Molecular & Clinical Medicine

Background:SGLT2 inhibitor treatment has been shown to have additional benefits
such as weight loss, renoprotective and cardioprotective effects. The present study was
conducted to assess role of SGLT2 inhibitors in elderly obese uncomplicated DM
patients.
Materials & Methods:84type II DM patients of both genders were prescribed
empagliflozin or dapagliflozin. FBG, PPBG, HbA1c, liverenzymes and kidney function
tests, complete urinalysis,serum lipids, protein excretion in spot urine were
recordedbefore and after the initiation of SGLT2 inhibitor.
Results: Out of 84 patients, males were 50 and 34 were females. SGLT2 inhibitor used
wereEmpagliflozin in 40 and Dapagliflozin in 44. Comorbidities were hyperlipidemia in
57, hypertension in 62, CAD in 12 and heart failure in 7 patients. Complications were
diabetic nephropathy in 15, diabetic retinopathy in 10 and diabetic neuropathy in 22
patients. The difference was significant (P< 0.05). Laboratory findings before and after
treatment in FBG (mg/dl) was 198.2 and 154.3, PPBG (mg/dl) was 276.2 and 235.9,
HbA1c (%) was 9.5 and 7.1, hemoglobin (g/dl) was 13.5 and 14.2, hematocrit (%) was
43.2 and 45.0, urea (mg/dl) was 36.4 and 38.7, creatinine (mg/dl) was 0.8 and 0.9 and
eGFR (mL/min/1.73 m2) was 84.2 and 79.5 respectively. The difference was significant
(P< 0.05).
Conclusion: Glycemic control was successfully achieved with SGLT2 inhibitor
treatment in type II DM patients.